-
公开(公告)号:US20170073395A1
公开(公告)日:2017-03-16
申请号:US15155324
申请日:2016-05-16
申请人: Pfizer Inc.
CPC分类号: C07K16/00 , C07K16/18 , C07K16/40 , C07K16/464 , C07K2317/24 , C07K2317/565 , C07K2317/92 , C07K2317/94
摘要: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
摘要翻译: 本文公开了人源化抗体,其中人种系残基引入非人供体抗体的互补决定区(CDR)。 本文还描述了抗体可变结构域(例如,噬菌体展示文库)的文库和用于筛选人源化抗体的方法。
-
公开(公告)号:US20200157212A1
公开(公告)日:2020-05-21
申请号:US16614701
申请日:2018-06-08
发明人: Stephen Berasi , Janet Elizabeth Buhlmann , Eric M. Bennett , Nathan Higginson-Scott , Huilan Gao , Zong Sean Juo , Stefano V. Gulla , Christine Huard , Sreekumar R. Kodangattil , Jian Li , Weining Lu , Xueping Fan , David J. Salant
摘要: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
-
公开(公告)号:US20180179285A1
公开(公告)日:2018-06-28
申请号:US15309879
申请日:2015-05-13
申请人: Pfizer Inc.
发明人: Eric M. Bennett , Nathan Higginson-Scott , Lioudmila Tchistiakova , Kimberly A. Marquette , Janet E. Paulsen , Ruth E. Gimeno
CPC分类号: C07K16/2863 , A61P27/16 , C07K16/00 , C07K16/24 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/522 , C07K2317/55 , C07K2317/75 , C07K2317/92
摘要: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
-
公开(公告)号:US10647756B2
公开(公告)日:2020-05-12
申请号:US15155324
申请日:2016-05-16
申请人: Pfizer Inc.
摘要: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
-
公开(公告)号:US20170313769A1
公开(公告)日:2017-11-02
申请号:US15581079
申请日:2017-04-28
发明人: Stefano V. Gulla , Christine Huard , Janet Elizabeth Buhlmann , Juan Carlos Almagro , Sreekumar R. Kodangattil , Steven A. Greenberg , Edward Roland Lavallie , Eric M. Bennett , Lidia Mosyak , James Perry Hall , Anthony John Coyle
IPC分类号: C07K16/24
摘要: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.
-
公开(公告)号:US20210163588A1
公开(公告)日:2021-06-03
申请号:US17092998
申请日:2020-11-09
发明人: Stefano V. Gulla , Christine Huard , Janet Elizabeth Buhlmann , Juan Carlos Almagro , Sreekumar R. Kodangattil , Steven A. Greenberg , Edward Roland Lavallie , Eric M. Bennett , Lidia Mosyak , James Perry Hall , Anthony John Coyle
IPC分类号: C07K16/24
摘要: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.
-
公开(公告)号:US20210040182A1
公开(公告)日:2021-02-11
申请号:US16836986
申请日:2020-04-01
申请人: Pfizer Inc.
摘要: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
-
公开(公告)号:US10392438B2
公开(公告)日:2019-08-27
申请号:US15309879
申请日:2015-05-13
申请人: Pfizer Inc.
发明人: Eric M. Bennett , Nathan Higginson-Scott , Lioudmila Tchistiakova , Kimberly A. Marquette , Janet E. Paulsen , Ruth E. Gimeno
摘要: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
-
公开(公告)号:US11578428B2
公开(公告)日:2023-02-14
申请号:US16836986
申请日:2020-04-01
申请人: Pfizer Inc.
摘要: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.
-
公开(公告)号:US11365253B2
公开(公告)日:2022-06-21
申请号:US16614701
申请日:2018-06-08
发明人: Stephen Berasi , Janet Elizabeth Buhlmann , Eric M. Bennett , Nathan Higginson-Scott , Huilan Gao , Zong Sean Juo , Stefano V. Gulla , Christine Huard , Sreekumar R. Kodangattil , Jian Li , Weining Lu , Xueping Fan , David J. Salant
IPC分类号: C07H21/04 , C12P21/06 , C12N15/87 , C12N1/20 , C12N15/74 , A61K39/00 , A61K39/395 , C07K16/00 , C07K16/28 , A61P13/12 , C12N15/85
摘要: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
-
-
-
-
-
-
-
-
-